Bachem Holding AG

Good morning ladies and gentlemen here in Zurich and online wherever you are joining from. Welcome to our full year 2025 results presentation. I am especially pleased to moderate today's session as it is the first results presentation in the new role of our CEO Ann-Kathrin Stoller. Joining us on stage as well is our CFO Alain Schafter. My name is Barbora Blaha and I am responsible for investor relations. So let's start with some remarks on the housekeeping. There will be sufficient time for questions after the presentation, and if you would like to ask a question, you can either type it into the Q&A box on the Zoom app at any time, so it's already open now, or simply raise your hand during the Q&A session if you're here in Zurich. And also, as always, this call is being recorded and the recordings will be uploaded on our webpage later today or tomorrow. So a few words on the agenda. First, Anne will provide a review of the year 2025. Then Alain will walk us through the financial results and Anne will close the presentation with an update on market environment and our business priorities for the current year. We expect this event to take about 60 minutes. And after the presentation, we will host an Aperol Riche here in this room and everyone attending in person is warmly invited to join. And with that, I am happy to hand over to Anne.

Thank you very much, Barbora. Good morning, everyone. A very warm welcome also from me to everybody here in Zurich and of course also to everybody joining us online. It's my great pleasure and honor to be here today and talk about the 2025 year results and also the outlook for 2026. So let's start. Let's start by looking a little bit back, 2025. It was a very good year. Our sales grew to 695.1 million Swiss francs, which is a growth of 14.8% or 19.2% in local currencies. Also, our EBITDA increased to 214.7 million Swiss francs, which is an EBITDA margin of 30.9%, and Alan will talk a little bit more about the effects behind that. As you are all aware, we are in a phase of strong growth, strong market growth, and also growth for Bachem, which means we are also investing a lot of money into our sites. In 2025, we invested 332.6 million Swiss francs, and we also grew in terms of personnel. We added more than 300 people to our workforce and we ended the year with 2,511 FTE. So if we look into our sales in a little bit more of a historic context, you see that we have been very consistently growing year over year. And this growth was even more emphasized, more pronounced, growing from 24 to 25. What is behind that growth? If you look at the distribution of the sales by top five customers and top 10 customers, we see that the share of our top five customers increased from 2024 to 2025. However, I would also like to remind everyone that these are the top five customers, and many of these customers have more than one product. So this is not the same as the top five products. We have our three distinct product categories, which are research and specialties, CNC development, and commercial API. And in 2025, all three of these product categories contributed to our growth. And we see that amongst those three, the CMC development contributed or grew the most. And on the next slide, I will talk a little bit more about each of these three categories and what was behind the growth that we saw. Commercial API is where ideally you primarily produce in campaigns, and we have seen in 2025 that we had more campaigns, longer campaigns, larger campaigns, and that had a lot of beneficial effects. On the one hand, it makes our production planning much more reliable, and also on the other hand, it has a positive effect on our equipment utilization. In addition to that, we launched a quite comprehensive operational excellence program in 2025 with a very strong focus last year on Bubendorf. We also see positive effects coming out of this operational excellence initiative. And we also, we had shift work before. We are producing shifts since many years, but we further extended shift work at our sites. If you look into CMC development, we see that our portfolio, our project portfolio is maturing. We'll also see a little bit more what that means on the next slide. But we also saw a strong effect from late stage projects where our customers asked us to also already build inventory for their pre-launch activities. So this means we have late stage projects here where we built stock prior to launch and so we would expect that some of these projects which in the future very likely show up in the commercial API category. For research and specialties, very much in line with what we have seen in recent years, the primary growth drivers are peptides, which are being used in either diagnostic or cosmetic applications. I already talked a little bit about our pipeline, our project pipeline in CMC development. On the one hand we see that we have more projects in later phases, but we also saw that in absolute numbers the number of projects went down a bit. That is due to a very careful project selection that we do. I think we've always said that for us, the main driver behind our pipeline is the quality of projects, not the quantity. And what I can say today is that we are very happy with our portfolio of projects, and we believe we have a very balanced pipeline. We already talked a little bit about growth and capacity expansion. So where did the more than 300 million of CARPEX investment go? We'll start looking into our Swiss sites. In Bubendorf, in building K, we made significant progress and we are very happy to report that we had a successful inspection by the RHI in 2025, which resulted in the manufacturing license for this first phase of the building K. But we also invested in our Bubendorf site beyond building K. We are making several investment projects there and working on those where we work on certain unit operations and add equipment selectively to address specific bottlenecks in some of our unit operations. We also invested into our Viuna site. As many of you know, that site is primarily focusing on producing precursors for peptide manufacturing, so that can be amino acid derivatives or diotripeptides. And so, especially in times as we see them right now, that is one of the great assets that we have to utilize that site to have an extra secure supply chain. We also made progress for our Sisslerfeld site, so on the one hand we acquired all five plots of land now, and we also founded our Barkem Sisslerfeld AG as a legal entity. And also we submitted a first permit application to build a utilities tunnel. So let's look beyond the ocean and look into our California sites. We have the Vista site, which is our large-scale manufacturing site in the US, and there we are working on further expanding our capacity, and that project is well on track. And in addition to that, looking even more into the future and potential future expansion, we also acquired a third building in Vista which is directly adjacent to the current two buildings. At the same time we're working on our Torrance site and at the Torrance site we are continuing our modernization efforts and also we are investing heavily into a higher degree of automation for the small scale manufacturing that we do at that site. We are not only relying on capacity expansion projects to increase capacity. I already briefly mentioned our operational excellence initiative. So, as I mentioned, the focus of that initiative was primarily in Bubendorf last year. But what we are generally working on is we work on a very large standardization. So across our network of sites, we want to use the same business processes, the same chemistry processes. We want to manufacture on the same type of equipment. And we see first results of those efforts. We also very much focus on communication especially communication on the manufacturing shop floor to make sure that this communication is very efficient and very fast and also to be very fast in the resolution of any challenges that we see in all communication measures that we have implemented focus primarily around that. I think in recent years we also talked about our network approach where we really specifically look into each site and the strength of that individual site and we carefully balance our portfolio with respect to those strengths of the sites. And if necessary and if it makes sense, we start to shift products from one site to another site to allow for extra space and capacity or because it makes more sense for that project to be manufactured at a different site. And that also helped us in 2025. So I would also like to mention in addition to all the business efforts and capacity expansion efforts, one strong focus area always was and will remain our sustainability efforts. I'm very happy to report that since many years we're working with EcoVadis. and also in 2025 we received a gold medal from Ecovades which puts us in the top 5% of all companies ranked by Ecovades and within the top 2% of companies ranked in our specific area of activity which is manufacturing for pharmaceutical products. We also joined the science-based targets initiative and we submitted our greenhouse gas emission reduction targets to that initiative and so we continue to work on various actions and various projects to continue our efforts in the sustainability area. That concludes my 2025 look back and I'm happy to hand over to Alan to talk more about the financial background.

Yes, so from my side, some financials review looking back in 2025. Anne already mentioned the sales 695 millions, the EBITDA over proportional growth in this year. I also want to highlight the net income with 148.8 million which brings the earnings per share almost to 2 Swiss Francs. Also we have later a slide the cash flow from operating activities which ended up with 271.6 million. Also for Bachem, the strong Swiss francs heavily impacted our numbers in 2025. So this table now represents the first on the local currency base. So we start with the 29.1% from last year. We see a slight dilution of 20 pips from the Cox area. This is because we invest there for the future growth. It's mainly labor cost. and this is what happened last year to people to achieve the growth in 26. On the marketing and sales, we kept the cost under proportional and therefore a positive impact in that space. On the R&D, we spent 1.5% of our sales into that area. It's very important. This is to keep our leadership in innovation and technology in the tight business. We are still in the range, even if it's a little bit less than last year, we always said 1.5 to 2% of the annual sales in that area. The G&A part, we are investing there. We have additional functions that we need as a growing company. We add where we see a need for the growing company, so also there a slight positive impact on the margin. With all of that in local currency, an underlying business we would have a margin of 30.2% in 2025, which is an increase of 110 pips compared to the last year. And then, as mentioned, the strong Swiss franc brought our margin down below 29% in 2025. And this is the first time we show something like a recurring underlying business, but we thought we had these two in the line. Other income, we had two special impacts, special items, which brought EBITDA to 30.9 as a reported number. The two impacts are, one is a sale of a building in the U.S., It was an old building. It was not on the site in Torrens or Vista. It was more in the San Francisco area and has been rented out over the last few years to a third party. Now we sold it in 2025. And the other part is a contribution from external parties to the project Sisterfeld. So we received money there, milestones, and this is reflected in the other income because it cannot be shown as a revenue. When we look at the cash flow, 214.7 million as a starting point, almost 38 million more than in the previous year. We pay taxes as we all have to do, 10 million accounts receivable. We see a positive impact and this is mainly driven by a more evenly distributed sales in the last few months of the year. On the inventory side, we have an increase. This includes raw material, work in progress, semi, finished goods. Some of the material that we have there, the raw material, is partially prepaid by the customers to support the working capital, and this is all needed to produce in 26 the demand from our customers that we can deliver into 26 on the purchase orders we have received from them. On the prepayments from our customer, this includes prepayments for capex, but also includes prepayments for working capital, as mentioned, for labor costs or material. There we see a net inflow of 85.4 million in 2025. And the change, the increase in payables and accruals, this is mainly driven by the course of the business. Growing business means usually more bills and more accruals in that area. So overall operating cash flow, 271.6 million in 25. Thereof, we spent, so cash out for our capex was 329.4 million. We mentioned the sale of the building that brought cash-in of 3.5 million in 2025, overall 325 million in the investing cash flow. On the financing part, we had the dividend from 2024 distributed, 63.7 million. A part of that 33 million has been kept in-house in the company as a loan from our main shareholder, IngroFinanz AG. And in addition, we have thrown down loans from the banks of 24.3 million in 2025. So overall, we see a net decrease of 64.1 million in the last year. Some key figures on the balance sheet. One on the left side where we start, net debt. As mentioned, we have drawn down loans during 2025. One is the majority shareholder, others are the bank. We ended up with a net debt of 26 million by the end of last year. And we will continue to, you saw the numbers, you see the investment plans we have, that this should not be a surprise that we will also use banks or third parties in the future for financial support. On the prepayment side from customers, by talking financial support, you saw the 85.4 million we received net this year, it ended up with a balance of 369 million. They are of 182 million are non-current, which means we have to pay back this money now to our customers through product supplies in 2026. So non-current means over the course of 12 months. On the balance sheet side, we grew the whole balance sheet first time over $2 billion. It's an increase of 10%. The equity also increased, but not that much, to $1.5 billion, so thereof a slight decrease in the ratio to 69% for 2025. On the CapEx side, Anne already mentioned, we're going to invest further. We have to invest. We invested $332.6 million in 2025. $295 million out of that was for capacity expansion, be it buildings or equipment. The overall number, 48% of our total sales invested in that area. We will invest further. We see the need. We need to invest to follow our growth strategy that we have. So for 2026, we see above 400 million right now. And to preempt maybe the question, we also said that last year, that 400 million as a capex, we are lower than this number. And there's two reasons. One is We had contingencies and plans, of course, you have to do that. Luckily, we didn't use that at the end of the day. And second, there can always be shifts from one project maybe to a next year. So, no worries that big projects are delayed because of that. And with that, back to the future, 2026.

Yes, so let's look into 2026, and I would like to do that by starting to look a little bit more into the peptide and oligonucleotide market. So we see a continued strong demand for peptides and oligonucleotides manufactured by chemical synthesis. and there are several drivers behind this continued strong demand and some of them are listed here on this slide. So first of all, we see an increasing complexity of the molecules in development. I remember 20 years ago when I joined Barkham, most peptides were linear, 20 to 30 more peptides. Those times have changed. We see cyclic peptides, constrained peptides. We see conjugated peptides with side chains, unnatural amino acids, you name it. And the same is true for oligonucleotides. We are starting to see more and more complexity also in that space. So that's good for us because chemical synthesis is extremely versatile and we can address all kinds of different modifications. We also see that demand is growing that is on the one hand based on indications. So both more indications, partially in rare diseases, but also in very large patient populations. But we also see demand is increasing because of new ways of administration. And one, of course, that is also very much in the public domain right now is oral administration, which we all know uses quite a lot of more API. So all of these factors are driving an increased need for chemically synthesized tides. Looking a little bit more specifically into the peptide market, we see a strong pipeline growth, and the majority of that pipeline growth is driven by oncology indications and also metabolic indications. Overall, there are about 1,000 peptides in development, and a little under half of these are in clinical development. And we also see a growth in Phase III project, which is also in line with what we have seen earlier in the numbers for the Barkham pipeline. So what are trends that we see in peptide drug development? One is very obviously a strong driver and strong focus on metabolic indications. There's a lot of press around those and a lot of excitement. What we also see is that we have a spillover or a halo effect. So this strong interest in peptides for metabolic indications has re-sparked an overall interest in peptides. I mean, we are in this space since 50 years. For us, peptides always were in the focus. For the pharmaceutical industry, that was not always the case, but we now see a very strong renewed interest in peptides as a drug target overall. And I already talked about the increasing complexity. So that means by being able to modify and conjugate peptides, they also become targets which are more easily druggable. So administration and half-life and the time between doses are all very positive effects by being able to make these very complex molecules. We are also very excited, very happy about what we see in the oligomarket, both internally as a contribution to our CMC development product category, but also what is happening in the market. There's a very strong growth also in oligonucleotides in development. We see here roughly that we have almost the same number of oligonucleotides in development as peptides, just a little bit lower. And the share of products in clinical development is also a little bit lower at 30%. That is not surprising because if you look at the oligonucleotide market and oligonucleotide development compared to peptides, this area is much younger. So it's, from a timing perspective, slightly behind or slightly shifted in time. But we also see here that cardiovascular indications are a large share of the pipeline which also speaks to now much larger indications historically when we look at the first approvals in the oligonucleotide field. They were all in orphan diseases. We now see, if we look at more recent approvals or also in the late-stage projects, we see much larger indications in much larger patient populations and also some activities in the metabolic space, for example. So also here, looking a little bit into trends, one very prominent one that we are all very excited about is, of course, the extrahepatic delivery. So all targets so far on the market was primarily targeting the liver. The next big chapter for oligonucleotides will come by being able to address other targets, and there are some very promising developments in that area. We also already talked about the broader patient populations, broader indications, which will increase the product demand and also will drive further innovation in how we manufacture tides or oligonucleotides in this case. And of course, a trend that is also very much one that we all read a lot about in the news is AI. So we also see AI is changing the way that drug discovery works also in the oligonucleotide field. So what does that mean for Barkham? At Barkham, we have three distinct operating modes, and I would like to briefly explain those and highlight those on this slide. Let's start on the left-hand side. This is the area that we call the trailblazing CDMO. And in this trailblazing CDMO, we work very much on research and development. And Alan mentioned we invested 1.5% of our sales into our own development and research. to develop products or drugs, that's not our area, but we develop new manufacturing technologies or we use new technologies that are out there on the market and apply them to tights manufacturing. and we do this very deliberately, always have and so this is the area where we really look into those new technologies and new developments either on the chemistry side or on equipment side or other areas and we then use those and apply them to first real case projects and products. And hopefully, if they're successful, they then develop into the middle part, which is the classical CDMO part. This is where we work with all our partners to support them during their clinical development phase with material for phase one, two, three, but also with a lot of services, analytical services, regulatory services, process development services. And we then apply what we learned on these new technologies, and we work with our customers to use them in the clinical development. And, of course, the ultimate goal finally is both for the products as well as for these technologies to make it into the right part, which is the commercial manufacturing of larger volumes of drugs. commercially approved APIs for drugs. And so that is the ultimate goal. We work on all three of these areas, and we have examples for technology innovation in all three of those areas. So I think this is really one area where historically we always had this focus on innovation, and we now really see that that pays off. So coming now to specific ideas and results and expectations for 2026. What we primarily will focus on is of course a very reliable execution on our manufacturing with respect to existing contracts and to fulfill what our customers need for us. We also, and that is a big part of that, we also will ramp up our production in Building K. So that is a very strong focus area for this year. And at the same time, looking beyond Building K, we are working on partnerships for the Sissler Feld site. And then we also want to look beyond what happens at Barkham overall. What and where do we go as a company? What is our next chapter? We work on that together with the executive team and also with the board. And we look very much forward to presenting the results of that exercise at our Capital Markets Day in November. So looking at some numbers, this is where we expect to be in 2026. We expect our sales to grow 35 to 45% in local currencies and also our profitability, meaning our EBITDA margin to be in the low 30s again in local currencies. I think that concludes the outlook for 2026, and we are very happy to answer any questions.

Thank you, Anne. Let's move on to the Q&A. And again, if you would like to ask a question, you can either type it into the Q&A box on Zoom and please use the Q&A box and not the chat. Or if you're here in this room, just simply raise your hand and we will stop by. So the first question comes from Sibyl.

Thank you very much for the presentation. I have a question about the outlook and you were hit quite heavily by currencies in 2025. Could you give us any hint about what you expect on the top line and on the margin, how much they are affected by currencies? And my second question, Cecil felt you have this extraordinary positive inflow of effect. Can we expect another 13 million in 2026 or is the outlook without extraordinary effects? Thank you.

I can answer the first question. So the impact now with the actual rates we see compared to the rates from last year, I would expect millions low 30s on top line and low 20s on EBITDA. So about 70 million from top line is impacting the EBITDA with the actual rates. And on the second, I would not expect something similar in 2026.

Okay, next question, Tanya.

Hi, Tanya Henslick from UBS. So I was wondering for the guidance for 2026, you gave range for us, can you give us the building blocks for the lower and upper end of the range and maybe the contribution you expect from Building K and the base business, and also if there's a bit of the U.S. ramp in there. And then my second question is on the customary ramp-up. When do you expect commercial deliveries for this one? Just to think about the phasing for H1 and H2, please. Thank you.

So for the 2026 guidance, Building K obviously in the ramp up in Building K has a very strong contribution to that guidance and to the growth that we expect. We don't disclose any specific numbers. But also based on, as we say, this ramp up will appear in phases. And right now we are on target with respect to that ramp up. The primary contribution from this ramp up we will see in our revenues in the second half of the year. So we expect a much stronger second half of 2026 than first half.

Okay. Estelle?

Yes, hello. Estelle Betrise from Berenberg. Just to maybe build on the Sisslefeld, you talked about the partnerships, so if you can elaborate a bit more what's the plan here. Originally it was a bit more of a one can open a client, like what are your expectations right now and where do you stand? And then in terms of financing also, how you talked about third party also financing, so if you could elaborate a bit further on that, please. Yes.

I can start with the Sisslefeld question. So we are in negotiations with several parties on Sisslefeld and as long as these negotiations are ongoing, we cannot comment on any details. And then for the second question, which I, as far as I understood, was around the financing, I think the general financing question I would give to Alan.

So you've seen we have taken out loans in 25. I have right now enough credit lines with banks that doesn't make me feel sleepless in the night. We are evaluating the best option. It's still no equity linked instrument is planned at the moment. So it will be third party loans and we are working on that, but no bad feelings to finance that growth in the next years.

Okay. Dani?

Thanks, Barbara. I was a bit surprised when you talked about Sisslerfeld milestone. At first glance I thought it's maybe a cantonal subsidy, but when you talk about milestone, does it mean you have an anchor client? You always talked about you only build Sisslerfeld when you have an anchor customer. Is that the correct interpretation? If so, it would of course be very nice to hear.

It doesn't have to be one anchor customer. It can be also several anchor customers. And the payment was based on a contractual term where we reached a certain milestone, and that payment was then the result of reaching that milestone.

There's no anchor customer site right now.

In what indication that is? Obviously with the GLP-1 cooling down until the end of the decade, it's difficult to interpret as an outsider.

Yeah, so I think what we can say is, or what we said in the past, is the Zissler Feld site will be a site for large-scale manufacturing. It will be a pure production site for large-scale products. And, well, obviously the majority, not all, but the majority of product that require manufacturing at that scale are in this obesity or metabolic area.

On the slide, if oncology drugs in phase 3 on the market, it's actually a higher amount of drugs than metabolic, but I guess the volume in oncology is of course much smaller, but probably more profitable for you in the end when compared to the large contracts in GLP-1. Let's say if the famous customer B, once you named a few years ago, is not so successful as the market believes, does it mean that you can repurpose some of the second part in Building K to oncology? Or will that happen somewhere else, in Torrens or in Vista? I think you see the direction of the question. Thank you.

So maybe to start on the first part, I would not... say that oncology products per se have a lower margin, right? The volumes, I fully agree with the volumes are lower, but I think they still, these products across all indications still make a very nice contribution to our margin. and then the to the second part of the question the equipment that we built is generally multi-purpose equipment so we can manufacture peptides on these equipment that doesn't mean we can only manufacture peptides for certain indications however The equipment has a certain size, and that means the product that needs to go into that equipment also needs to have a certain batch size. And I briefly talked about our network strategy. So within Barkham, we have a network of sites that range from smaller scale, for example, at the Torrens site to large scale now in Building K and in the future in Sisslerfeld. And we really try to be very deliberate about where does a project fit and what site is the optimal fit for that project.

Good. Let's take some questions from the other side. Laura?

I'm Laura Pfeiffer from Octavian. Thanks for taking my question. I would like to come back first on the sales guidance. I understand you don't give out an exact split, but maybe can you indicate how much growth could come from the base business? So excluding Building K, can this be, I don't know, 10 to 15 percent? And then I guess the rest is depending on Building K. So a little bit more color here would be appreciated. And then also is there the potential for an upside if things go really well in the ramp-up phase? And then secondly, maybe on the margin guidance, you say low 30s ABDA margin in local currencies. This compares to 30.2%, the clean base from 25. So can you clarify what is low 30s? This is 32, 33%. And then also why are you so highly confident given that you still have the dilution from the new capacity in it? So just a little bit more clarity maybe on the margin drivers. And then just very quickly maybe on your first kind of feedback from the ramp up of the first line, how is that progressing and what are you learning so far?

I hope I still remember the first question correctly. So, yes, I think what we can say is the majority of the growth will have to come out of Building K. We don't provide specific numbers, but it's a mixture, of course, of the base business and ramp up also in other facilities, but the majority comes out of Building K. and the current ramp-up plans and manufacturing plans go according to plan and any upside or downside is currently reflected in our guidance. And I think the other one is probably a question.

Yeah, on the marching, I mean, we say low 30s, this can be between 30 and 33. We see like we have a... a bigger bandwidth on the top line with 35 to 45. And we also see, depending where this goes, it can impact the margin. So that's why I also leave this range there of low 30s. There is always something can happen in a ramp up, not only top line, but also cost wise. And that's why we keep this low 30s. But I would say we don't want to be lower than this year, of course.

Good. Any other question?

Again for the building K and the ramp up, sometimes you say the ramp up will take place. Does this mean there is actually no commercial production taking place right now or what is the stage right now?

We have started with production. So the ramp up is going according to the plan. So we are manufacturing in the first lines.

Okay, let's take some questions online. So Amit Thakkar is asking, can you update us on the capacity outlook for Sizzlefeld, specifically your ability and timing to fill the site and how you're thinking about demand sustainably given recent softer GLP-1 related data and any potential pricing implications?

Yeah, so the Zissefeld is a very large piece of land and there will be, once the site is fully built out, there will be several buildings and we will grow into that site as we have always done it as we have also done it in Bubendorf piece by piece and bit by bit and that will be done in very strong coordination with our customers so we will build the site at the pace that is required by the market But we still see a very strong demand for products or specifically also for metabolic indications. So therefore, we still believe that this site will add a great benefit to both Barcom as well as our customers and their patients.

and maybe also a related question to the demand online from Zain Ibrahim. Can you remind us how much of Building K is booked currently and what your confidence level is in being able to fill up Building K based on your latest conversation with customers?

A very large portion of Building K is already fully booked. I think we made announcements over the last few years on customers with contracts, so we are very confident about the utilization of Building K. Okay.

Sibyl, maybe?

Thank you. You're going to invest more than 400 million in CapEx. Could you remind us how much will be maintenance CapEx and how much will be growth CapEx and how much was it in 2025? And additionally, I expect also your customer financing some CapEx. How much will it be this year? Thank you very much.

So on the first question, we... Out of the 332, it was 295 was capacity expansions. So the remaining part, it's a similar relation that it was in the previous year. So you can imagine it's about the same. The big part still goes into capacity globally. On the side, how much do we expect? We had in the first few months already, again, a positive inflow from customers which are contractually agreed in the past. I would not expect other big numbers coming in 2026, so you saw the non-current part of the liability. I would more expect a cash outflow in 2026 from prepayments.

Okay, and follow-up question from Tanya, please, in the back.

I wanted to ask some questions on the U.S. expansion. I think $250 million is your planned investment for that. How much of this, if you could give us an indication, is backed by also customer prepayments or minimum commitments? And when should we expect the first revenue contributions from the capacity expansions? I have a second question. And also the second question is on an update on Oligos. You mentioned the potential of the market on your site. Can you give us maybe an update on your exposure or what we can expect from Oligos medium term for Bachem? Thank you.

We are very pleased with what we see right now from the oligonucleotides, so we see a very nice growth in that area. We expect this nice trend to continue, but of course, compared to the peptides, it's still a relatively small part. And on the US side, we expect that we will see first output from the current ongoing capacity project in Vista next year, so in 2027.

Thank you. Maybe one question here in front, Andi.

Could you give us some insight in how much ethics did cost since you gave us the 1 billion guidance a few years back?

Yes, I can. I did that calculation and it hurt a bit. So when we gave the guidance, when we calculate today's numbers with that local currency from that day, it's about 80 to 90 million we lost on top net and about two-thirds of that on EBITDA.

Let's take some more online questions. So Finn Scherzler from Deutsche Bank is asking on customers A and B, how flexible are your contract volumes here? For example, if one truck does much better and one worse than expected, have the forecasts you received from your customer changed as of late?

No, they have not. So we still have contracts where we have forecasts from customers, long-term forecasts, and a certain binding period in the forecast, and right now we don't see any changes to those.

And then a question from Chris Richardson from Jefferies. What are the phases of the ramp for building K? Is it separate lines or something else?

Yeah, we talk about phases, not lines, because one line can consist, one phase can consist of several lines. So we are now ramping up phase, the phase one lines, and then later in the year, we expect the ramp up from the phase two.

And we will take some questions online. Another question from Chris is, what is your timeline to signing an anchor customer for Syslafeld to hit the end of decade target?

We hope to be able to make announcements on partnerships for Syslafeld still this year.

and continuing with Chris questions. Could you please also clarify what the contributing factors for the 35% growth in CMC development in financial year 25 was its new capacity, price or higher efficiency?

I think a very large driver behind that was the build up of inventory for pre-launch activities. So I think the strongest driver behind that obviously is more campaign mode, more larger scale manufacturing and also larger volumes in that category.

Good, then a question from Charles Weston, RBC. When might you negotiate a Customer A contract extension? Your peer announced an extension this morning from their large customer.

Contract negotiations will happen in time for us to renew the contract, and as long as there's nothing signed, we will not comment on any ongoing negotiations.

Thank you. Some more questions here in the room? Yeah, in the front, please.

I would have an understanding question. You mentioned the rising complexity as such. Could you maybe allude a bit on that in terms of competitive advantages, Bachem having existed for 52 years, having the brightest brains basically on those developments. How should we expect market shares to develop over the next 5-10 years?

Yeah, it's absolutely correct that Barkham probably has the longest experience in the market and also historically has always had this very strong focus on innovation and being able to manufacture very complex molecules. And so in that area, we certainly have very distinct competitive advantage where customers come to us and we are able to manufacture product that other companies in that area have not been successful with.

So is it fair to assume that the 40% market share currently is rather to be expected to be stable or increasing again in your favor due to maybe geopolitics as well?

We need to be a bit careful to distinguish the number of projects where I think, yes, we have that advantage and we may see more projects with more complex molecules. But when you look at market share in terms of sales, it's obviously primarily very large volume projects driving that. And some of these more complex molecules are in large indications, but some of them are also in very small niche indications.

Any other questions here in the room? Daniel, in the front.

Merci, merci. Just one. On the IMTA margin target for this year, When I do the bridge calculation, let's say starting base is adjusted 28.5. You say low 30, so let's say 32. I guess Forex will shift away 100 pips or so, 150. Then you end up with 200 pips underlying margin improvement. which is in my view quite substantial what makes you so confident i mean you have all the ramp up effects okay you have the first customer building k which is up and running so i guess the extra costs there are out but you will have the extra cost for the next customer beginning commercial scale up in 27 and so on and so on. So just to understand the dilutive effects where they are overcompensated, it's quite a significant step up.

I mean, I think there are two points. One is the Cox area, where we mentioned and we also saw it here now, where the gross profit is slightly diluted because we have costs. But we also build costs in for the ramp up in the budget, which is the base for the guidance, of course. So something can happen. But the main positive contributor then is if we keep GM Day marketing sales, the R&D stable, there will be, like this year in 25, a positive contribution. And with that, just for mathematical reason, the margin should go up. Because if we keep those underproportional, we will not grow marketing and sales in GM Day by 40%, hopefully. So there is a positive impact on the margin just from this big jump in the sales.

And a somewhat related question online from Peter Testa. Is there any phasing for the utilization of Bubendorf's existing capacity as Building K is ramped? Will there be underutilization in phases of the years as products are transferred and new products ramped up?

I would not expect that to be the case. So while we then transfer projects over to Building K, we saw we have a very healthy pipeline that is also maturing to later stage development projects. So that means we expect the capacity that we will free up in our existing manufacturing buildings to be filled by those projects.

Okay, thank you. Any other questions here from the audience? Then a last question from Zain Ebrahim, JP Morgan. How should we think about the margin development from here in 27 and beyond? And what is your exposure to energy costs and are these fully passed through to customers?

On the margin side, we see over the next few years slightly increase every year with the growth that's the economy of scale so we see going up every year slightly so the base we said 30% that really should be a base what it should go above in the next few years constantly every year on the energy cost it's I would say meet single-digit millions So it's an amount, it's not substantial in the overall cost, and some or many of the contracts allow us to pass such costs through to the customer.

Okay, thank you. There are no other questions online. Last chance to ask questions here in the room, which is not the case. So before we close this event, let me briefly mention our upcoming events, which is the annual general meeting on April 29th. Our half year results on July 30 and Capital Markets Day, as already mentioned, on November 26. And also our mandatory legal disclaimer. And with that, I would like to thank everyone for your interest and your time and wish you a great day. Thank you.